drugset
drugset / Trial / NCT00585416

Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer

NCT00585416 ↗

Phase 2 Terminated 23 enrolled University of Wisconsin, Madison Progen Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research is to determine the effectiveness of CGC-11047 in subjects with metastatic hormone refractory prostate cancer as measured by changes in PSA.

Timeline

Start
2006-06
Primary completion
2007-11
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject CGC-11047 Unknown — Intravenous

Indications

prostate cancer